<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2024-16-3-63-70</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-1663</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Нарушения липидного и углеводного обменов у детей с хроническим гепатитом С</article-title><trans-title-group xml:lang="en"><trans-title>Lipid and carbohydrate metabolism disturbances in children with chronic hepatitis C</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никифорова</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikiforova</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никифорова Александра Олеговна – младший научный сотрудник научно-исследовательского отдела вирусных гепатитов и заболеваний печени</p><p>тел.: +7-967-343-90-59, 8(812)234-34-16 </p><p>Санкт-Петербург </p></bio><bio xml:lang="en"><p> Saint-Petersburg </p></bio><email xlink:type="simple">alexa-nikiforova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Грешнякова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Greshnyakova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Грешнякова Вера Александровна – руководитель научно-исследовательского отдела вирусных гепатитов и заболеваний печени; доцент кафедры инфекционных заболеваний у детей ФП и ДПО, к.м.н.</p><p>тел.: +7-981-763-82-03 </p><p>Санкт-Петербург </p></bio><bio xml:lang="en"><p> Saint-Petersburg </p></bio><email xlink:type="simple">veramamayeva@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жирков</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhirkov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жирков Антон Анатольевич – младший научный сотрудник научно-исследовательского отдела клинической лабораторной диагностики </p><p>Санкт-Петербург </p></bio><bio xml:lang="en"><p> Saint-Petersburg </p></bio><email xlink:type="simple">ant-zhirkov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексеева Лидия Аркадьевна – заведующий научно-исследовательским отделом клинической лабораторной диагностики, д.б.н.</p><p>тел.: 8(812)234-34-18 </p><p>Санкт-Петербург </p></bio><bio xml:lang="en"><p> Saint-Petersburg </p></bio><email xlink:type="simple">kldidi@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Детский научно-клинический центр инфекционных болезней</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pediatric Research and Clinical Center for Infectious Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Детский научно-клинический центр инфекционных болезней;&#13;
Санкт-Петербургский государственный педиатрический медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pediatric Research and Clinical Center for Infectious Diseases;&#13;
Saint-Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>09</month><year>2024</year></pub-date><volume>16</volume><issue>3</issue><fpage>63</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Никифорова А.О., Грешнякова В.А., Жирков А.А., Алексеева Л.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Никифорова А.О., Грешнякова В.А., Жирков А.А., Алексеева Л.А.</copyright-holder><copyright-holder xml:lang="en">Nikiforova A.O., Greshnyakova V.A., Zhirkov A.A., Alekseeva L.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/1663">https://journal.niidi.ru/jofin/article/view/1663</self-uri><abstract><p>Цель: изучить состояние липидного и углеводного обменов, состава тела, структуры паренхимы печени у детей с хроническим гепатитом С.Материалы и методы: 63 ребенка с ХГС, обследованных в Детском научно-клиническом центре инфекционных болезней в 2022–2023 гг. (антропометрия, лабораторное обследование, биоимпедансный анализ состава тела, эластография печени с оценкой стеатоза).Результаты: отклонения показателей липидного обмена были выявлены у 1/3 детей с хроническим гепатитом С даже при нормальном и низком индексе массы тела. У 54% детей с ХГС обнаружены признаки формирования инсулинорезистентности (HOMA-IR&gt;3,2). У трети пациентов с резистентностью к инсулину выявлен стеатоз печени, что значительно превышает частоту регистрации стеатоза среди детей без инсулинорезистентности. Имеется тенденция к увеличению частоты инсулинорезистентности пропорционально прогрессированию стадии фиброза печени. Не обнаружено связи между генотипом вируса гепатита и нарушениями липидного и углеводного обменов.Выводы. В результате воздействия вируса гепатита С у детей с хроническим гепатитом С повышается риск формирования инсулинорезистентности, что может являться одним из патогенетических механизмов развития стеатоза печени, повышая риск формирования выраженного фиброза печени и неблагоприятного исхода заболевания.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study the state of lipid and carbohydrate metabolism, body composition, liver parenchyma structure in children with chronic hepatitis C (CHC).Materials and methods. 63 children with CHC examined at DNACIB in 2022–2023 (anthropometry, laboratory examination, bioimpedance analysis (BIA) of body composition, liver elastography with evaluation of steatosis).Results. Abnormalities of lipid metabolism were detected in 1/3 of children with CHC even with normal and low body mass index (BMI). Signs of insulin resistance (HOMAIR&gt;3,2) were found in 54% of children with CHC. One third of patients with insulin resistance have liver steatosis, which significantly exceeds the frequency of steatosis registration among children without insulin resistance. There was a tendency for the frequency of insulin resistance to increase in proportion to the progression of the stage of liver fibrosis. No association between hepatitis virus genotype and disorders of lipid and carbohydrate metabolism was found.Conclusion. As a result of hepatitis C virus exposure in children with CHC, the risk of insulin resistance formation increases, which may be one of the pathogenetic mechanisms of liver steatosis development, increasing the risk of severe liver fibrosis formation and unfavorable outcome of the disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический вирусный гепатит С у детей</kwd><kwd>стеатоз печени</kwd><kwd>фиброз печени</kwd><kwd>инсулинорезистентность</kwd><kwd>нарушения липидного обмена</kwd><kwd>нарушения углеводного обмена</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic viral hepatitis C in children</kwd><kwd>liver steatosis</kwd><kwd>liver fibrosis</kwd><kwd>insulin resistance</kwd><kwd>lipid metabolism disturbances</kwd><kwd>carbohydrate metabolism disturbances</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hepatitis C/WHO [Internet]. [cited 2023 March 17]. Available from: https://www.who.int/ru/news-room/factsheets/detail/hepatitis-c</mixed-citation><mixed-citation xml:lang="en">Hepatitis C/WHO [Internet]. [cited 2023 March 17]. Available from: https://www.who.int/ru/news-room/factsheets/detail/hepatitis-c</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Diagnosing hepatitis C/ American Liver Foundation. [Internet]. [cited 2023 March 17]. Available from: https://liverfoundation.org/liver-diseases/viral-hepatitis/hepatitis-c/diagnosing-hepatitis-c/</mixed-citation><mixed-citation xml:lang="en">Diagnosing hepatitis C/ American Liver Foundation. [Internet]. [cited 2023 March 17]. Available from: https://liverfoundation.org/liver-diseases/viral-hepatitis/hepatitis-c/diagnosing-hepatitis-c/</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Melikoki, V. Seroprevalence of Hepatitis C in Children Without Identifiable Risk-Factors: A Systematic Review and Meta-Analysis/ V. Melikoki, G. Kourlaba, I. Kanavaki [et al.]// J Pediatr Gastroenterol Nutr. – 2021. – Vol. 72. – № 6. – Р. 140-148. doi: 10.1097/MPG.0000000000003099.</mixed-citation><mixed-citation xml:lang="en">Melikoki, V. Seroprevalence of Hepatitis C in Children Without Identifiable Risk-Factors: A Systematic Review and Meta-Analysis/ V. Melikoki, G. Kourlaba, I. Kanavaki [et al.]//J Pediatr Gastroenterol Nutr. – 2021. – Vol. 72. – № 6. – Р. 140-148. doi: 10.1097/MPG.0000000000003099.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bortolotti, F. Long-term course of chronic hepatitis C in children: From viral clearance to end-stage liver disease/F. Bortolotti, G.Verucchi, C.Camma[et al.]// Gastroenterology.- 2008.- Vol.134. – P. 1900–1907. doi: 10.1053/j.gastro.2008.02.082</mixed-citation><mixed-citation xml:lang="en">Bortolotti, F. Long-term course of chronic hepatitis C in children: From viral clearance to end-stage liver disease/F. Bortolotti, G.Verucchi, C.Camma[et al.]// Gastroenterology.- 2008.- Vol.134. – P. 1900–1907. doi: 10.1053/j.gastro.2008.02.082</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">European Paediatric Hepatitis, C.V.N. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 2005, 41, 45–51. doi: 10.1086/430601</mixed-citation><mixed-citation xml:lang="en">European Paediatric Hepatitis, C.V.N. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 2005, 41, 45–51. doi: 10.1086/430601</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jara, P.; Resti, M.; Hierro, L.; Giacchino, R.; Barbera, C.; Zancan, L.; Crivellaro, C.; Sokal, E.; Azzari, C.; Guido, M.; et al. Chronic hepatitis C virus infection in childhood: Clinical patterns and evolution in 224 white children. Clin. Infect. Dis. 2003, 36, 275–280. doi: 10.1086/345908</mixed-citation><mixed-citation xml:lang="en">Jara, P.; Resti, M.; Hierro, L.; Giacchino, R.; Barbera, C.; Zancan, L.; Crivellaro, C.; Sokal, E.; Azzari, C.; Guido, M.; et al. Chronic hepatitis C virus infection in childhood: Clinical patterns and evolution in 224 white children. Clin. Infect. Dis. 2003, 36, 275–280. doi: 10.1086/345908</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pokorska-S ́piewak, M.; Kowalik-Mikołajewska, B.; Aniszewska, M.; Pluta, M.; Walewska-Zielecka, B.; Marczyńska, M. Determinants of liver disease progression in children with chronic hepatitis C virus infection. Pol. J. Pathol. 2015, 66, 368–375. doi: 10.5114/pjp.2015.57248</mixed-citation><mixed-citation xml:lang="en">Pokorska-Śpiewak, M.; Kowalik-Mikołajewska, B.; Aniszewska, M.; Pluta, M.; Walewska-Zielecka, B.; Marczyńska, M. Determinants of liver disease progression in children with chronic hepatitis C virus infection. Pol. J. Pathol. 2015, 66, 368–375. doi: 10.5114/pjp.2015.57248</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guido, M.; Bortolotti, F.; Leandro, G.; Jara, P.; Hierro, L.; Larrauri, J.; Barbera, C.; Giacchino, R.; Zancan, L.; Balli, F.; et al. Fibrosis in chronic hepatitis C acquired in infancy: Is it only a matter of time? Am. J. Gastroenterol. 2003, 98, 660–663. doi: 10.1111/j.1572-0241.2003.07293.x</mixed-citation><mixed-citation xml:lang="en">Guido, M.; Bortolotti, F.; Leandro, G.; Jara, P.; Hierro, L.; Larrauri, J.; Barbera, C.; Giacchino, R.; Zancan, L.; Balli, F.; et al. Fibrosis in chronic hepatitis C acquired in infancy: Is it only a matter of time? Am. J. Gastroenterol. 2003, 98, 660–663. doi: 10.1111/j.1572-0241.2003.07293.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Modin, L.; Arshad, A.; Wilkes, B.; Benselin, J.; Lloyd, C.; Irving, W.L.; Kelly, D.A. Epidemiology and natural history of hepatitis C virus infection among children and young people. J. Hepatol. 2019, 70, 371–378. doi: 10.1016/j.jhep.2018.11.013</mixed-citation><mixed-citation xml:lang="en">Modin, L.; Arshad, A.; Wilkes, B.; Benselin, J.; Lloyd, C.; Irving, W.L.; Kelly, D.A. Epidemiology and natural history of hepatitis C virus infection among children and young people. J. Hepatol. 2019, 70, 371–378. doi: 10.1016/j.jhep.2018.11.013</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Хронический гепатит С / К.В. Жданова [и др.] // Руководство по инфекционным болезням в 2 кн. / под ред. акад. РАМН проф. Ю.В. Лобзина и проф. К.В. Жданова. – Кн. 2. – СПб.: ООО «Издательство Фолиант», 2011. – С. 203–211.</mixed-citation><mixed-citation xml:lang="en">Xronicheskij gepatit S/ K.V. Zhdanova, D.A. Gusev, K.V. Kozlov, D.M. Shaxmanov// Rukovodstvo po infekcionny`m boleznyam/ pod red. akad. RAMN prof. Yu.V. Lobzina i prof. K.V. Zhdanova. – V 2 kn. – Kn.2. – SPb.: OOO «Izdatel`stvo Foliant», 2011. – S. 203-211.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020 Jan;51(2):216-230. doi: 10.1111/apt.15575</mixed-citation><mixed-citation xml:lang="en">Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020 Jan;51(2):216-230. doi: 10.1111/apt.15575</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017 Dec 16;390(10113):2627-2642. doi: 10.1016/S0140-6736(17)32129-3</mixed-citation><mixed-citation xml:lang="en">Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017 Dec 16;390(10113):2627-2642. doi: 10.1016/S0140-6736(17)32129-3</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017 Jun;128:40-50. doi: 10.1016/j.diabres.2017.03.024.</mixed-citation><mixed-citation xml:lang="en">Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017 Jun;128:40-50. doi: 10.1016/j.diabres.2017.03.024.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016 May 25;17(6):803. doi: 10.3390/ijms17060803.</mixed-citation><mixed-citation xml:lang="en">Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci. 2016 May 25;17(6):803. doi: 10.3390/ijms17060803.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Хронический гепатит С и неалкогольная жировая болезнь печени. Основные аспекты патогенеза / К.В. Жданов [и др.] // Вестник Российской Военно-медицинской академии. – 2018. – № 1 (61). – С. 216-221. – doi: 10.17816/brmma12326</mixed-citation><mixed-citation xml:lang="en">Khronicheskii gepatit S i nealkogol’naya zhirovaya bolezn’ pecheni. Osnovnye aspekty patogeneza/ Zhdanov K.V., Karyakin S.S., Kozlov K.V. [i dr.]// Vestnik Rossiiskoi Voennomeditsinskoi akademii. - 2018.- № 1 (61).- S. 216-221.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines. 2021 Oct 17;9(10):1491. doi: 10.3390/biomedicines9101491.</mixed-citation><mixed-citation xml:lang="en">Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, Yu ML, Wang SC. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines. 2021 Oct 17;9(10):1491. doi: 10.3390/biomedicines9101491.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Глобальные стратегии сектора здравоохранения по ВИЧ, вирусному гепатиту и инфекциям, передаваемым половым путем, на 2022–2030 гг. / Всемирная организация здравоохранения [Internet]. [cited 2022 Jul 18]. Available from: https://www.who.int/ru/publications/i/item/9789240053779</mixed-citation><mixed-citation xml:lang="en">Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. [Internet]. [cited 2022 Jul 18]. Available from: https://www.who.int/ru/publications/i/item/9789240053779</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr;47(7):1012-1022. doi: 10.1111/apt.14554</mixed-citation><mixed-citation xml:lang="en">Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr;47(7):1012-1022. doi: 10.1111/apt.14554</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Влияние противовирусной терапии на снижение риска развития метаболического синдрома у больных хроническим гепатитом С / А.Ф. Новикова [и др.] // Журнал инфектологии. – 2023. – Т. 15, № 2. – С. 132–138. – doi: 10.22625/2072-6732-2023-15-2-132-138</mixed-citation><mixed-citation xml:lang="en">Vliyanie protivovirusnoi terapii na snizhenie riska razvitiya metabolicheskogo sindroma u bol’nykh khronicheskim gepatitom S / A. F. Novikova, D. A. Kokorev, D. Yu. Konstantinov, L. L. Popova // Zhurnal infektologii. – 2023. – T. 15, № 2. – S. 132-138. doi: 10.22625/2072-6732-2023-15-2-132-138</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Васюкова О.В. Инсулинорезистентность при ожирении у детей: спорность оценки / О.В. Васюкова, А.В. Витебская // Проблемы Эндокринологии. – 2009. – Т. 55, № 3. – С. 8–12. – doi: 10.14341/probl20095538-12</mixed-citation><mixed-citation xml:lang="en">Vasyukova O.V. Insulinorezistentnost` pri ozhirenii u detej: spornost` ocenki/ O.V. Vasyukova, A.V. Vitebskaya// Problemy` E`ndokrinologii. – 2009.-T.55, №3. – S. 8-12. doi: 10.14341/probl20095538-12</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Элиминация HCV-инфекции: история с продолжением / К.В. Жданов [и др.] // Журнал инфектологии. – 2018. – Т. 10, № 4. – С. 6–13. – doi: 10.22625/2072-6732-2018-10-4-6-13.</mixed-citation><mixed-citation xml:lang="en">Eliminatsiya HCV-infektsii: istoriya s prodolzheniem / K. V. Zhdanov, K. V. Kozlov, V. S. Sukachev [i dr.] // Zhurnal infektologii. – 2018. – T. 10, № 4. – S. 6-13. doi: 10.22625/2072-6732-2018-10-4-6-13.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira LP, de Jesus RP, Boulhosa RS, Onofre T, Mendes CM, Vinhas L, Waitzberg DL, Lemaire DC, Cavalcante LN, Lyra AC, Lyra LG. Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes. J Am Coll Nutr. 2016 Jul;35(5):436-42. doi: 10.1080/07315724.2015.1072756.</mixed-citation><mixed-citation xml:lang="en">Oliveira LP, de Jesus RP, Boulhosa RS, Onofre T, Mendes CM, Vinhas L, Waitzberg DL, Lemaire DC, Cavalcante LN, Lyra AC, Lyra LG. Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes. J Am Coll Nutr. 2016 Jul;35(5):436-42. doi: 10.1080/07315724.2015.1072756.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Alzahrani N. Hepatitis C virus, insulin resistance, and diabetes: A review. Microbiol Immunol. 2022 Oct;66(10):453-459. doi: 10.1111/1348-0421.13023.</mixed-citation><mixed-citation xml:lang="en">Alzahrani N. Hepatitis C virus, insulin resistance, and diabetes: A review. Microbiol Immunol. 2022 Oct;66(10):453-459. doi: 10.1111/1348-0421.13023.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Жданов, К.В. Гепатит С и неалкогольная жировая болезнь печени у пациентов с ВИЧ-инфекцией / К.В. Жданов, К.В. Козлов, В.С. Сукачев // ВИЧ-инфекция и иммуносупрессии. – 2017. – № 1 (9). – С. 36–42. – doi: 10.22328/2077-9828-2017-9-1-36-42</mixed-citation><mixed-citation xml:lang="en">Zhdanov, K.V. Gepatit S i nealkogol’naya zhirovaya bolezn’ pecheni u patsientov s VICh-infektsiei/ K.V. Zhdanov, K.V. Kozlov, ̆ V.S. Sukachev // VICh-infektsiya i immunosupressii. – 2017. – № 1 (9). – S. 36–42. doi: 10.22328/2077-9828-2017-9-1-36-42</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Неинвазивная диагностика стеатоза печени у пациентов с ХГС / К.В. Жданов [и др.] // Нерешенные вопросы этиотропной терапии актуальных инфекций: Материалы Всероссийской ежегодной научно-практической конференции, Санкт-Петербург, 05–06 декабря 2022 года. – СПб.: Санкт-Петербургская общественная организация «Человек и его здоровье», 2022. – С. 42–52. – ISBN: 978-5-6046956-4-7</mixed-citation><mixed-citation xml:lang="en">Neinvazivnaya diagnostika steatoza pecheni u patsientov s KhGS / K. V. Zhdanov, M. V. Yaremenko, K. V. Kozlov [i dr.] // Nereshennye voprosy etiotropnoi terapii aktual’nykh infektsii : Materialy Vserossiiskoi ezhegodnoi nauchno-prakticheskoi konferentsii, Sankt-Peterburg, 05–06 dekabrya 2022 goda. – Sankt-Peterburg: Sankt-Peterburgskaya obshchestvennaya organizatsiya «Chelovek i ego zdorov’e», 2022. – S. 42-52. ISBN: 978-5-6046956-4-7</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
